Proinflammatory cytokines promote tau aggregation by inducing cleavage in human Alzheimer’s disease
This study reveals that proinflammatory cytokines drive Alzheimer's disease tau aggregation by activating the immunoproteasome to induce specific tau cleavage, thereby identifying a novel inflammation-responsive pathway and therapeutic target for tauopathies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human brain is a vast network of cells that rely on a delicate internal balance to function and survive. Among the many proteins that keep these cells running is a molecule called tau, which acts like a structural scaffold, helping to maintain the internal highways that transport nutrients and signals. In a healthy brain, tau stays soluble and moves freely. However, in Alzheimer's disease, this protein begins to clump together into rigid, tangled masses that clog the cell's machinery and eventually lead to cell death. For decades, scientists have known that inflammation—a general state of immune system activation—is a major feature of Alzheimer's, but the exact way this inflammation triggers the deadly clumping of tau has remained a mystery. Understanding this link is crucial because if inflammation is the spark that starts the fire of protein aggregation, then calming that inflammation could potentially stop the disease before the damage becomes irreversible.
A team of researchers has now uncovered a direct mechanical link between the brain's immune response and the formation of these toxic tau tangles. By examining brain tissue from 46 people with Alzheimer's disease and 40 people without the condition, the scientists used advanced chemical analysis to map exactly how the tau protein was being cut apart. They discovered that in the diseased brains, the tau protein was being sliced into specific fragments that were missing their protective ends. These fragments, which are rich in a sticky core region, were found to be the primary building blocks of the tangles. The study reveals that this cutting process is not random; it is driven by a specific cellular machine called the immunoproteasome, which is normally part of the immune system's defense against viruses and bacteria. In Alzheimer's, this machine is switched on by inflammatory signals, and instead of just cleaning up waste, it begins to chop tau into pieces that are primed to stick together.
The researchers traced this process back to its source by looking at the proteins present in the brain tissue. They found that the levels of the immunoproteasome were significantly higher in the brains of Alzheimer's patients, and these levels rose in direct proportion to the amount of tau cleavage. To confirm that inflammation was the cause, the team turned to living cells and mice. When they exposed human cells and mice to inflammatory signals known as cytokines, the cells immediately began to produce more of the immunoproteasome. This new machine then started cutting the tau protein in the exact same way seen in human patients, creating the same sticky fragments that rapidly formed tangles. Crucially, this happened even without any pre-existing clumps to start the process, proving that inflammation alone is enough to initiate the disease mechanism.
To test whether stopping this process could prevent the damage, the researchers used a drug called Baricitinib, which is already approved to treat other inflammatory conditions. When they treated the cells and mice with this drug, it blocked the inflammatory signal that turns on the immunoproteasome. As a result, the cutting of the tau protein stopped, and the formation of toxic tangles was effectively prevented. This finding suggests that the immune system, when overactive, can accidentally turn a protective protein into a destructive one. The study does not just show that inflammation and tau clumps exist together; it demonstrates that one causes the other through a specific, identifiable pathway. By identifying this chain of events, the research offers a clear target for new treatments: if doctors can dampen this specific inflammatory response, they might be able to stop the tau protein from being cut and clumping, potentially slowing or halting the progression of Alzheimer's disease in its earliest stages.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.